I’m doing some research on this stock, seems like it could be a moonshot or burnout stock. What y’all say?
ImmunityBio (NASDAQ: IBRX) is a small/mid-cap biotech focused on cancer immunotherapy. It just received FDA-approval for a bladder cancer drug ANKTIVA.
ImmunityBio is trying to train/boost the immune system (especially NK cells + T cells) to fight cancer more effectively and for longer duration.
Their flagship product is ANKTIVA (nogapendekin alfa inbakicept-pmln), an IL-15 receptor agonist designed to activate immune cells.
FDA progress
ImmunityBio announced a Type B End-of-Phase meeting with the FDA regarding its supplemental Biologics License Application for ANKTIVA plus Bacillus Calmette–Guérin in BCG-unresponsive non-muscle invasive bladder cancer. The FDA requested additional information but did not require new clinical trials. ImmunityBio plans to submit the requested data within 30 days, supporting a potential resubmission without further trials. This reduces regulatory uncertainty and supports the stock’s rally.
⸻
Analyst upgrade
Piper Sandler maintained an Overweight rating on ImmunityBio and raised its price target from $5 to $7. This upgrade reflects increased confidence in the company’s regulatory progress and commercial prospects, contributing to positive investor sentiment and the stock’s strong gain.
Revenue and trial updates
ImmunityBio reported a 700% revenue increase in 2025, driven by rapid growth of its lead drug Anktiva. Clinical trials.
I bought a few stocks yesterday m, just to test the waters. It seems to be very high risk & high reward kind of stock. Thoughts?